News & Updates
This issuance expands global protection for Kinetic River’s technologies aimed at expanding the power of flow cytometry Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Oct. 1, 2021 /PRNewswire/ — Kinetic River Corp., a leader in custom flow cytometry instrumentation, announced today having been issued a patent from the Japanese Patent Office covering its innovative technologies…
Read More
Excerpt from the Press Release: LYON, France and CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) — Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from its Phase 1 clinical trial of AZP-3601, a potential treatment for hypoparathyroidism, at the American Society for Bone…
Read More
New research published today in Science Advances describes precise mechanism of how Alu reverse transcription occurs from RNA to cDNA, and its subsequent triggering of inflammasome activation and consequent cell death in Geographic Atrophy (GA) – the most severe form of dry age-related macular degeneration. Research shows Alu RNA/cDNA reverse transcription confined to rim of…
Read More
Excerpt from the Press Release: MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) — Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. (“Apollomics”), an innovative biopharmaceutical company committed to the discovery and development of mono- and…
Read More
Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Sept. 29, 2021 /PRNewswire/ — Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced a phase I/II clinical study of KRAS G12C inhibitor IBI351…
Read More
Excerpt from the Press Release: SAN FRANCISCO, Sept. 29, 2021 /PRNewswire/ — Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) to provide technology-powered patient support and distribution services through Phil’s proprietary workflow to enhance the patient’s access to therapy. Trudhesa is indicated for the acute treatment of…
Read More
Brings deep industry experience to support commercialization plan Excerpt from the Press Release: FRAMINGHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced the appointment of Larry Hicks to its Board of Directors. Mr.…
Read More
Decision taken to move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data Oxurion is moving into Part B of study evaluating THR-149 against aflibercept THR-149 is a potent plasma kallikrein inhibitor for the treatment of the 40-50% of DME patients who respond…
Read More
92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average hospital length of stay in patients treated with TRV027 compared to placebo TRV027 is currently being evaluated in a randomized controlled study (NIH ACTIV-4) and a global adaptive…
Read More
Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer. Excerpt from the Press Release: “This study demonstrates the clinical value of urine-based liquid biopsy testing to provide…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?